Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2021

Open Access 01-12-2021 | Cholangiocarcinoma | Research

The prognostic value of arginase-1 and glypican-3 expression levels in patients after surgical intrahepatic cholangiocarcinoma resection

Authors: Zeyuan Qiang, Haofeng Zhang, Shuai Jin, Cao Yan, Zhen Li, Lianyuan Tao, Haibo Yu

Published in: World Journal of Surgical Oncology | Issue 1/2021

Login to get access

Abstract

Background

The aim of this study was to investigate the prognostic value of arginase-1 (Arg-1) and glypican-3 (GPC-3) in patients with intrahepatic cholangiocarcinoma (ICC).

Methods

Two hundred and thirty-seven patients with ICC were included in this study. All patients had undergone radical surgery and had complete clinical information. Immunohistochemistry was used to assess the levels of Arg-1 and GPC-3 in ICC tissues. Univariate and multivariate analyses were conducted to identify independent risk factors in ICC. The relationship between Arg-1 and GPC-3 levels and patient survival was determined using the Kaplan-Meier method.

Results

High Arg-1 and GPC-3 expression levels were associated with poor prognosis in patients with ICC, and they could be as new prognostic biomarkers in ICC.

Conclusion

Arg-1 and GPC-3 can serve as independent prognostic biomarkers in ICC.
Appendix
Available only for authorised users
Literature
1.
Saha S, Zhu A, Fuchs C, Brooks G. Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 2016;21(5):594–9.PubMedPubMedCentralCrossRef
2.
Li H, Hu B, Zhou Z, Guan J, Zhang Z, Zhou G. Hepatitis C virus infection and the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis of 16 case-control studies. World J Surg Oncol. 2015;13:161.PubMedPubMedCentralCrossRef
3.
Shaib Y, Davila J, McGlynn K, El-Serag H. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40(3):472–7.PubMedCrossRef
4.
von Hahn T, Ciesek S, Wegener G, Plentz R, Weismüller T, Wedemeyer H, et al. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol. 2011;46(9):1092–8.CrossRef
5.
Yamamoto Y, Sugiura T, Todaka A, Okamura Y, Ito T, Ashida R, et al. Surgical indication for advanced intrahepatic cholangiocarcinoma according to the optimal preoperative carbohydrate antigen 19-9 cutoff value. World J Surg. 2018;42(10):3331–40.PubMedCrossRef
6.
Jackson M, Amini A, Jones B, Rusthoven C, Schefter T, Goodman K. Treatment selection and survival outcomes with and without radiation for unresectable, localized intrahepatic cholangiocarcinoma. Cancer J (Sudbury, Mass.). 2016;22(4):237–42.CrossRef
7.
Saxena A, Meteling B, Kapoor J, Golani S, Morris D, Bester L. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients. Ann Surg Oncol. 2015;22(3):794–802.PubMedCrossRef
8.
9.
Munder M. Arginase: an emerging key player in the mammalian immune system. British J Pharmacol. 2009;158(3):638–51.CrossRef
10.
Ho M, Kim H. Glypican-3: a new target for cancer immunotherapy. Eur J Cancer (Oxford, England: 1990). 2011;47(3):333–8.CrossRef
11.
Jing X, Liang H, Hao C, Yang X, Cui X. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncol Rep. 2019;41(2):801–10.PubMed
12.
Liu J, Zuo X, Wang S. Diagnosis accuracy of serum Glypican-3 level in patients with hepatocellular carcinoma and liver cirrhosis: a meta-analysis[J]. Eur Rev Med Pharmacol Sci. 2015;19(19):3655.PubMed
13.
de Boniface J, Mao Y, Schmidt-Mende J, Kiessling R, Poschke I. Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients[J]. Oncoimmunology. 2012;1(8):1305–12.PubMedPubMedCentralCrossRef
14.
Labib O, Harb O, Khalil O, Baiomy T, Gertallah L, Ahmed R. The diagnostic value of arginase-1, FTCD, and MOC-31 expression in early detection of hepatocellular carcinoma (HCC) and in differentiation between HCC and metastatic adenocarcinoma to the liver. J Gastrointestinal Cancer. 2020;51(1):88–101.CrossRef
15.
Zhang Z, Zhou Y, Hu K, Huang Y. Investigating effects of preoperative inflammatory biomarkers on predicting survival outcomes of intrahepatic cholangiocarcinoma after curative resection. World J Surg Oncol. 2020;18(1):272.PubMedPubMedCentralCrossRef
16.
Yamashita S, Morine Y, Imura S, Ikemoto T, Saito Y, Takasu C, et al. A new pathological classification of intrahepatic cholangiocarcinoma according to protein expression of SSTR2 and Bcl2. World J Surg Oncol. 2021;19(1):142.PubMedPubMedCentralCrossRef
17.
Liu H, Qiu G, Hu F, Wu H. Fibrinogen/albumin ratio index is an independent predictor of recurrence-free survival in patients with intrahepatic cholangiocarcinoma following surgical resection. World J Surg Oncol. 2021;19(1):218.PubMedPubMedCentralCrossRef
18.
Wang H, Wang H, Chen T, Liang X, Song Y, Wang J. Evaluation of the POSSUM, P-POSSUM and E-PASS scores in the surgical treatment of hilar cholangiocarcinoma. World J Surg Oncol. 2014;12:191.PubMedPubMedCentralCrossRef
19.
Radwan N, Ahmed N. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diag Pathol. 2012;7:149.CrossRef
20.
Timek DT, Jianhui S, Haiyan L, Fan L. Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Am J Clin Pathol. 2012;2:203–10.CrossRef
21.
Ma Z, Lian J, Yang M, Wuyang J, Zhao C, Chen W, et al. Overexpression of Arginase-1 is an indicator of poor prognosis in patients with colorectal cancer. Pathol Res Pract. 2019;215(6):152383.PubMedCrossRef
22.
Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G. Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res. 2000;60(12):3305–12.PubMed
23.
Tao X, Wang B, Chen H, Huang A, Ye Y, Huang C, et al. Study on the clinical significance and correlation of arginase-1 and inducible nitric oxide synthase expression in hepatocellular carcinoma. Chinese J Hepatol. 2020;28:924–9.
24.
Bedoya A, Tate D, Baena A, Córdoba C, Borrero M, Pareja R, et al. Immunosuppression in cervical cancer with special reference to arginase activity. Gynecol Oncol. 2014;135(1):74–80.PubMedCrossRef
25.
Zea AH, Rodriguez PC, Culotta KS, Hernandez CP, Desalvo J, Ochoa JB, et al. L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol. 2004;232(1-2):21–31.PubMedCrossRef
26.
Zhang Y, Chen S, Li J, Dai W, Qian Y. Immune infiltrating cells in cholangiocarcinoma may become clinical diagnostic markers: based on bioinformatics analysis. World J Surg Oncol. 2021;19(1):59.PubMedPubMedCentralCrossRef
27.
Tian L, Ma J, Ma L, Zheng B, Liu L, Song D, et al. PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome. World J Surg Oncol. 2020;18(1):303.PubMedPubMedCentralCrossRef
28.
29.
30.
Filmus J, Church J, Buick R. Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol. 1988;8(10):4243–9.PubMedPubMedCentral
31.
Capurro M, Xiang Y, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65(14):6245–54.PubMedCrossRef
32.
Song H, Shi W, Xiang Y, Filmus J. The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem. 2005;280(3):2116–25.PubMedCrossRef
33.
Wang D, Gao Y, Zhang Y, Wang L, Chen G. Glypican-3 promotes cell proliferation and tumorigenesis through up-regulation of β-catenin expression in lung squamous cell carcinoma. Biosci Rep. 2019;39(6):BSR20181147.PubMedPubMedCentralCrossRef
34.
Zhou S, Parham D, Yung E, Pattengale P, Wang L. Quantification of glypican 3, β-catenin and claudin-1 protein expression in hepatoblastoma and paediatric hepatocellular carcinoma by colour deconvolution[J]. Histopathology. 2015;67(6):905–13.PubMedCrossRef
35.
Shibui Y, Miyoshi K, Kohashi K, Kinoshita Y, Kuda M, Yamamoto H, et al. Glypican-3 expression in malignant small round cell tumors. Oncol Lett. 2019;17(3):3523–8.PubMedPubMedCentral
36.
Stigliano I, Puricelli L, Filmus J, Sogayar M, Bal de Kier Joffé E, Peters M. Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. Breast Cancer Res Treat. 2009;114(2):251–62.PubMedCrossRef
37.
Geers J, Jaekers J, Topal H, Aerts R, Vandoren C, Boer GV, et al. Predictors of survival after surgery with curative intent for perihilar cholangiocarcinoma. World J Surg Oncol. 2020;18(1):286.PubMedPubMedCentralCrossRef
38.
Bose M, Mukherjee P. Microbe-MUC1 crosstalk in cancer-associated infections. Trends Mol Med. 2020;26(3):324–36.PubMedCrossRef
39.
Yang J. Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer. Med Oncol (Northwood, London, England). 2020;37(5):34.CrossRef
40.
Chen J, Tong W, Liao M, Chen D. Inhibition of arachidonate lipoxygenase12 targets lung cancer through inhibiting EMT and suppressing RhoA and NF-κB activity. Biochem Biophysi Res Commun. 2020;524(4):803–9.CrossRef
41.
Zhang D, Yang L, Liu X, Gao J, Liu T, Yan Q, et al. Hypoxia modulates stem cell properties and induces EMT through N-glycosylation of EpCAM in breast cancer cells. J Cell Physiol. 2020;235(4):3626–33.PubMedCrossRef
42.
Beatson R, Tajadura-Ortega V, Achkova D, Picco G, Tsourouktsoglou T, Klausing S, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016;17(11):1273–81.PubMedPubMedCentralCrossRef
Metadata
Title
The prognostic value of arginase-1 and glypican-3 expression levels in patients after surgical intrahepatic cholangiocarcinoma resection
Authors
Zeyuan Qiang
Haofeng Zhang
Shuai Jin
Cao Yan
Zhen Li
Lianyuan Tao
Haibo Yu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2021
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-021-02426-9

Other articles of this Issue 1/2021

World Journal of Surgical Oncology 1/2021 Go to the issue

Research

How accurate is frozen section pathology compared to permanent pathology in detecting involved margins and lymph nodes in breast cancer?

Research

Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer

Research

Identification of a ferroptosis-related gene signature predictive model in colon cancer

Case report

Breast cancer-associated opsoclonus-myoclonus syndrome: a case report

Research

Establishment of risk prediction model of postoperative pancreatic fistula after pancreatoduodenectomy: 2016 edition of definition and grading system of pancreatic fistula: a single center experience with 223 cases

Research

Loco-regional recurrence trend and prognosis in young women with breast cancer according to molecular subtypes: analysis of 1099 cases